PHS
VERV

PFM Health Sciences’s Verve Therapeutics VERV Stock Holding History

PFM Health Sciences’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-155,495
Closed -$711K – 76
2025
Q1 		$711K Buy
155,495
+29,496
+23% +$198K 0.05% 61
2024
Q4 		$711K Hold
125,999
– – 0.04% 80
2024
Q3 		$610K Buy
+125,999
New +$732K 0.03% 73
2023
Q3 		– Sell
-186,087
Closed -$3.49M – 86
2023
Q2 		$3.49M Hold
186,087
– – 0.14% 73
2023
Q1 		$2.68M Sell
186,087
-31,215
-14% -$611K 0.12% 69
2022
Q4 		$4.2M Sell
217,302
-951,506
-81% -$25.2M 0.15% 74
2022
Q3 		$40.1M Buy
1,168,808
+323,622
+38% +$10.3M 1.45% 29
2022
Q2 		$12.9M Buy
845,186
+475,421
+129% +$7.36M 0.49% 53
2022
Q1 		$8.44M Buy
+369,765
New +$10.6M 0.32% 57

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

PFM Health Sciences's VERV Position: Q2 2025 in Review

PFM Health Sciences sold out of Verve Therapeutics (VERV) in Q2 2025, closing a stake of 155,495 shares — an estimated $711K sold.

PFM Health Sciences first reported a position in VERV in Q1 2022 and held it in 9 quarters. The position peaked at $40.1M in Q3 2022. 175 funds tracked by Wall St. Rank hold VERV as of Q2 2025.

  • PFM Health Sciences reported no remaining Verve Therapeutics position as of Q2 2025 after selling out during the quarter.
  • PFM Health Sciences sold 155,495 Verve Therapeutics shares in Q2 2025, an estimated $711K.
  • PFM Health Sciences first reported a position in Verve Therapeutics in Q1 2022 and held it in 9 quarters.
  • PFM Health Sciences's Verve Therapeutics position peaked at $40.1M in Q3 2022.
  • 175 funds tracked by Wall St. Rank held Verve Therapeutics as of Q2 2025.

Based on PFM Health Sciences's 13F filing for Q2 2025, filed 14 Aug 2025.